Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 2, 2011, Pages 172-178

  Kim, J H ^a   Ann, J H ^a   Kim, M J ^a  

^a Gachon University   (South Korea)

Author keywords

atypical antipsychotics; depressive symptoms; subjective well being

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ACUTE DISEASE; ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; SCHIZOPHRENIA; SCORING SYSTEM; SUBJECTIVE WELLBEING UNDER NEUROLEPTICS SCALE; SYMPTOM; TREATMENT OUTCOME; WELLBEING;

EID: 79952256706     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01175.x     Document Type: Article

References (46)

1. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B, (2001) Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research, 50, 79-88. (Pubitemid 32510889)
2. Awad AG, Voruganti LN, (2004) Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs, 18, 877-893. (Pubitemid 39612017)
3. Karow A, Naber D, (2002) Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology, 162, 3-10. (Pubitemid 34639549)
4. Mizrahi R, Rusjan P, Agid O, Graff A, Mamo DC, Zipursky RB, Kapur S, (2007) Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. American Journal of Psychiatry, 164, 630-637. (Pubitemid 46650195)
5. Carder PC, Vuckovic N, Green CA, (2003) Negotiating medications: patient perceptions of long-term medication use. Journal of Clinical Pharmacy and Therapeutics, 28, 409-417. (Pubitemid 37352451)
6. Hansson L, (2006) Determinants of quality of life in people with severe mental illness. Acta Psychiatrica Scandinavica Supplementum, 429, 46-50. (Pubitemid 43340888)
7. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE, (2001) Quality of life in schizophrenia: contributions of anxiety and depression. Schizophrenia Research, 51, 171-180. (Pubitemid 32772850)
8. Fitzgerald PB, de Castella AR, Filia K, et al. (2003) A longitudinal study of patient- and observer-rated quality of life in schizophrenia. Psychiatry Research, 119, 55-62. (Pubitemid 36829418)
9. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA, (2004) Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Research, 129, 141-147. (Pubitemid 39601810)
10. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW, (2004) Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. Journal of Clinical Psychiatry, 65, 932-939.
11. Karow A, Moritz S, Lambert M, Schoder S, Krausz M, (2005) PANSS syndromes and quality of life in schizophrenia. Psychopathology, 38, 320-326. (Pubitemid 43074271)
12. Narvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL, (2008) Subjective and objective quality of life in schizophrenia. Schizophrenia Research, 98, 201-208. (Pubitemid 350235889)
13. Eack SM, Newhill CE, (2007) Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophrenia Bulletin, 33, 1225-1237. (Pubitemid 47347913)
14. Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A, (2005) Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. British Journal of Psychiatry, 187, 131-136. (Pubitemid 41139684)
15. Möller HJ, (2005) Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? European Archives of Psychiatry and Clinical Neuroscience, 255, 190-201.
16. Möller HJ, (2005) Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. European Archives of Psychiatry and Clinical Neuroscience, 255, 83-93.
17. Siris SG, (2000) Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. American Journal of Psychiatry, 157, 1379-1389.
18. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). Washington DC: American Psychiatric Association.
19. de Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L, (2002) Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology, 162, 24-28. (Pubitemid 34639552)
20. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D, (2003) Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. American Journal of Psychiatry, 160, 303-309. (Pubitemid 41110456)
21. de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D, (2008) Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry, 41, 125-128.
22. Naber D, Riedel M, Klimke A, et al. (2005) Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatrica Scandinavica, 111, 106-115. (Pubitemid 40293177)
23. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, Czekalla J, (2006) Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. Journal of Clinical Psychiatry, 67, 1690-1697. (Pubitemid 44955148)
24. Yoon JS, Kook SH, Lee HY, Lee C, Paik IH, (2000) The development of a Korean modification of the scale to measure Subjective Well-being under Neuroleptic Treatment (SWN). Journal of Korean Neuropsychiatric Association, 39, 987-998.
25. Kay SR, Fiszbein A, Opler LA, (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276. (Pubitemid 18039085)
26. Beck AT, Ward CH, Mendelson M, Mock J, Erbauch J, (1961) An inventory for measuring depression. Archives of General Psychiatry, 4, 561-571.
27. Hahn HM, Yum TH, Shin YW, Kim KH, Yoon DJ, Chung KJ, (1986) A standardization study of Beck Depression Inventory in Korea. Journal of Korean Neuropsychiatric Association, 25, 487-502.
28. Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP, (1994) Five-component model of schizophrenia: assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Resesarch, 52, 295-303. (Pubitemid 24225427)
29. Whitehorn D, Brown J, Richard J, Rui Q, Kopala L, (2002) Multiple dimensions of recovery in early psychosis. International Review of Psychiatry, 14, 273-283. (Pubitemid 35398853)
30. Inada T, Yagi G, Miura S, (2002) Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophrenia Research, 57, 227-238. (Pubitemid 35240025)
31. Kim JH, Jung HY, Kang UG, et al. (2002) Metric characteristics of the DIEPSS: a practical combined rating scale for drug-induced movement disorders. Movement Disorders, 17, 1354-1359. (Pubitemid 36041355)
32. Kim JH, Byun HJ, (2003) Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects. Clinical Neuropharmacology, 26, 312-316.
33. Kim JH, Cho SY, Byun HJ, Kang UG, Ahn YM, Kim YS, (2004) Multidimensional sensory phenomena in antipsychotic-induced akathisia. Journal of Clinical Psychopharmacology, 24, 618-623. (Pubitemid 39518657)
34. Mauri MC, Moliterno D, Rossattini M, Colasanti A, (2008) Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. Schizophrenia Research, 99, 7-12. (Pubitemid 351249117)
35. Addington D, Addington J, Maticka-Tyndale E, (1993) Assessing depression in schizophrenia: the Calgary Depression Scale. British Journal of Psychiatry Supplementum, 22, 39-44. (Pubitemid 23355888)
36. Hamilton M, (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62.
37. Siris SG, Addington D, Azorin JM, Falloon IR, Gerlach J, Hirsch SR, (2001) Depression in schizophrenia: recognition and management in the USA. Schizophrenia Research, 47, 185-197. (Pubitemid 32244103)
38. Mohr P, (2007) Quality of life in the long-term treatment and the role of second-generation antipsychotics. Neuroendocrinology Letters, 28 (Suppl. 1), 117-133. (Pubitemid 46534377)
39. Conley RR, Mahmoud R, (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 158, 765-774. (Pubitemid 32429846)
40. Peuskens J, Möller HJ, Puech A, (2002) Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology, 12, 305-310. (Pubitemid 34753101)
41. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO, (2004) Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 161, 1837-1847. (Pubitemid 39314678)
42. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF, (2000) Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naîve patients before and after treatment. American Journal of Psychiatry, 157, 1461-1466.
43. Newcomer JW, Miller LS, Faustman WO, Wetzel MW, Vogler GP, Csernansky JG, (1994) Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. British Journal of Psychiatry, 164, 834-838. (Pubitemid 24186907)
44. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A, (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research, 43, 135-145. (Pubitemid 30386882)
45. Fitzgerald PB, Williams CL, Corteling N, et al. (2001) Subject and observer-rated quality of life in schizophrenia. Acta Psychiatrica Scandinavica, 103, 387-392. (Pubitemid 32436752)
46. Lobana A, Mattoo SK, Basu D, Gupta N, (2001) Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatrica Scandinavica, 104, 51-55. (Pubitemid 32532330)